IPF vs. PPF: Understanding Progressive Fibrosis and Evolving Paradigms

Introduction

Interstitial Lung Disease (ILD) is an umbrella term encompassing over 200 distinct disorders characterized by inflammation and/or fibrosis in the lung interstitium. Among these, Idiopathic Pulmonary Fibrosis (IPF) has historically been the most prominent and lethal.

However, recent clinical consensus recognizes that many ILDs other than IPF (such as autoimmune-related ILDs or hypersensitivity pneumonitis) can also develop a self-sustaining, irreversible "progressive fibrosing phenotype." Once this switch is flipped, the lung degrades much like it does in IPF, regardless of the original underlying disease. This broader paradigm is termed Progressive Pulmonary Fibrosis (PPF).

This article explores the core definitions, the shared vs. distinct pathogenic mechanisms of IPF and PPF, and the evolutionary shift in their treatment paradigms.

1. Defining IPF vs. PPF

IPF (Idiopathic Pulmonary Fibrosis)

Definition: A specific form of chronic, progressive fibrosing interstitial pneumonia of unknown cause. It primarily affects older adults (typically men over 50). Diagnosis requires the radiological or histological hallmark pattern of "Usual Interstitial Pneumonia (UIP)."
Characteristics: By the time of diagnosis, irreversible scarring is already established. Historically, the median survival was a mere 3–5 years, proving more fatal than many common cancers.

PPF (Progressive Pulmonary Fibrosis)

Definition: Formally codified in the 2022 ATS/ERS/JRS/ALAT clinical practice guidelines¹. PPF refers to any non-IPF fibrosing ILD (e.g., Rheumatoid Arthritis-ILD, Systemic Sclerosis-ILD, chronic Hypersensitivity Pneumonitis) that continues to exhibit worsening respiratory symptoms, lung function decline, or radiological progression despite standard appropriate management (like immunosuppression).
Previous Terminology: Often referred to in earlier literature as PF-ILD (Progressive Fibrosing ILD).

In simple terms: IPF is a disease that fibroses from day one for unknown reasons. PPF is a state where a lung, originally damaged by a known trigger (like autoimmune inflammation), eventually enters an unstoppable, IPF-like fibrotic downward spiral.

2. Pathogenesis: The Shared Path to Self-Destruction

While the initiating triggers for IPF and PPF differ, they eventually converge on a common final pathway of progressive, self-sustaining (autonomous) fibrosis.

IPF Mechanism: Epithelial-Driven Aberrant Repair

The exact cause of IPF remains unknown, but the prevailing theory is the "epithelium-driven paradigm."

The Trigger: Repetitive micro-injuries to alveolar epithelial cells (AECs) caused by a combination of aging, genetics (e.g., telomere dysfunction), and environmental insults (e.g., smoking).
Aberrant Repair: Instead of normal epithelial regeneration, the damaged IPF epithelium mounts an abnormal repair response, hyper-secreting profibrotic cytokines like TGF-β, FGF, and PDGF.
Fibroblast Activation: These cytokines signal resident fibroblasts to differentiate into highly active myofibroblasts. These cells relentlessly secrete massive amounts of extra-cellular matrix (ECM), such as collagen.
Self-Perpetuation: The newly stiffened, scarred ECM creates mechanical stress on surrounding healthy cells, physically squeezing them and triggering even more TGF-β release. This creates a vicious, autonomous "loop of death" independent of external triggers.

PPF Mechanism: Escaping Immune Control

Most diseases that lead to PPF (like Autoimmune ILD) initially start as classic inflammation.

Early Stage (Inflammation-Dominant): Lymphocytes and macrophages infiltrate the lung, releasing inflammatory cytokines. At this stage, corticosteroids and immunosuppressants are highly effective in halting the damage.
Progression (Fibrotic Autonomy): If chronic inflammation repeatedly damages the lung architecture over years, it inadvertently activates the exact same aberrant repair pathways seen in IPF (TGF-β release, myofibroblast activation).
Immune Independence: Once this fibrotic cascade gains momentum, it becomes autonomous. Even if aggressive immunosuppression successfully turns off the original immune-driven inflammation, the mechanical and biochemical fibrotic loop continues to progress. This "escape" marks the transition to PPF.

3. The Evolution of Treatment: Anti-Fibrotics for All?

The realization that IPF and PPF share a common final pathogenic pathway profoundly changed the medical approach.

1. IPF-Exclusive Era

For years, direct anti-fibrotic drugs (Nintedanib and Pirfenidone) were strictly approved only for IPF. These drugs successfully slow down the rate of lung function (FVC) decline by approximately 50%.

2. The INBUILD Trial & The Rise of PPF

"If the final fibrotic mechanism is the same, shouldn't anti-fibrotics work for any progressive fibrosing disease?" This hypothesis was famously proven by the landmark INBUILD trial². In this study, the broad-spectrum tyrosine kinase inhibitor Nintedanib (which blocks FGF, PDGF, and VEGF receptors) was given to patients with any non-IPF progressive fibrosing ILD (i.e., PPF patients).

The Result: Nintedanib reduced the annual rate of FVC decline by an impressive 57% across the board, demonstrating efficacy virtually identical to its performance in IPF, completely independent of the underlying original diagnosis.

Because of this, anti-fibrotic therapy is no longer an "IPF-only" weapon. It is now a standard, critical intervention for managing PPF driven by autoimmune diseases, environmental exposures, and more.

4. Implications for Preclinical Drug Discovery

When discovering new drugs, selecting an animal model that reflects these distinct phases is crucial:

Evaluating Inflammation-Driven Fibrosis (PPF-like):
- The standard Bleomycin-Induced Pulmonary Fibrosis Model is excellent for this. It causes acute inflammation followed by a wave of fibrosis. It is highly useful for initially testing drugs that might halt the transition from inflammation to fibrosis.
The Quest for True IPF Models:
- Because the bleomycin model naturally resolves over several weeks (lacking the "autonomous progression" of true human IPF), scientists are increasingly using advanced models, such as repetitive bleomycin dosing, aged-mouse models, telomerase-deficient mice, or Precision-Cut Lung Slices (PCLS), to better mimic the relentless, progressive nature of human disease.

5. Conclusion

IPF (idiopathic fibrosis from the start) and PPF (fibrosis resulting from exhausted inflamed lungs) take different roads but arrive at the same destination: runaway myofibroblast activation and collagen deposition. Discovering this "common fibrotic pathway" led to the breakthrough expansion of anti-fibrotic treatments. Moving forward, the race is on for next-generation anti-fibrotics—targeting TGF-β integrins, cellular senescence, and mechanotransduction—to not just slow, but potentially arrest or reverse this devastating fibrotic loop.

References

1. Raghu G, et al. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022;205(9):1048-1073. 2. Flaherty KR, et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases (INBUILD). N Engl J Med. 2019;381(18):1718-1727. PubMed